Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer

28 Jan 2020  ·  Heyrim Cho, Zuping Wang, Doron Levy ·

Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its limited success, so far, in treating solid cancers, it is increasingly successful, demonstrating to have a broader therapeutic potential... In this paper we develop a mathematical model to study the efficacy of engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines. We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2. We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell line, but not in the CaSki cell line. read more

PDF Abstract
No code implementations yet. Submit your code now



  Add Datasets introduced or used in this paper

Results from the Paper

  Submit results from this paper to get state-of-the-art GitHub badges and help the community compare results to other papers.


No methods listed for this paper. Add relevant methods here